Skip to content

RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy

Randomized Controlled Trial of Olanzapine for the Control of Chemotherapy-induced Vomiting in Children Receiving Highly Emetogenic Chemotherapy

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03118986
Enrollment
161
Registered
2017-04-18
Start date
2017-08-10
Completion date
2026-06-12
Last updated
2026-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematopoietic System--Cancer, Nausea, Oncology, Vomiting in Infants and/or Children

Keywords

olanzapine, vomiting, children, adolescents, bone marrow transplant, supportive care

Brief summary

Chemotherapy-induced nausea and vomiting (CINV) are among the most bothersome symptoms during cancer treatment according to children and their parents. Most children receiving highly emetogenic chemotherapy (HEC), including those receiving hematopoietic stem cell transplant (HSCT) conditioning, experience CIV despite receiving antiemetic prophylaxis. Olanzapine improves CINV control in adult cancer patients, has a track record of safe use in children with psychiatric illness, does not interact with chemotherapy and is inexpensive. We hypothesize that the addition of olanzapine to standard antiemetics will improve chemotherapy-induced vomiting (CIV) control in children receiving highly emetogenic chemotherapy

Interventions

DRUGOlanzapine

olanzapine 0.1 mg/kg/dose (maximum 10 mg/dose) by mouth as a single daily dose based on actual body weight

DRUGPlacebo Oral Tablet

Placebo tablets that look like olanzapine and will be dosed as if they are olanzapine

Sponsors

The Hospital for Sick Children
Lead SponsorOTHER
University of California, San Francisco
CollaboratorOTHER
Children's Mercy Hospital Kansas City
CollaboratorOTHER
St. Justine's Hospital
CollaboratorOTHER
Columbia University
CollaboratorOTHER
Medical University of South Carolina
CollaboratorOTHER
CancerCare Manitoba
CollaboratorOTHER
University of North Carolina, Chapel Hill
CollaboratorOTHER
Nationwide Children's Hospital
CollaboratorOTHER
All India Institute of Medical Sciences
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
30 Months to 18 Years
Healthy volunteers
No

Inclusion criteria

Planned receipt of HEC or cyclophosphamide ≥ 1 g/m2/day (≥ 33 mg/kg/day) for cancer treatment or autologous or allogeneic HSCT conditioning.81,82 Examples of HEC are: busulfan IV (myeloablative dosing), carboplatin ≥175mg/m²/dose, cisplatin ≥12mg/m²/dose, cytarabine ≥3g/m²/day, melphalan \>140mg/m², methotrexate ≥12g/m²/dose and thiotepa ≥300mg/m²/dose. Plan for inpatient admission from administration of first study drug dose until 24 hours following administration of last study drug dose. Body weight of at least 12.5 kg 2.5 to \< 18 years of age. Note that the minimum age requirement corresponds to an approximate body weight of 12.5 kg. Samples for all laboratory tests will be obtained within one week prior to administration of the first chemotherapy dose of the study chemotherapy block or the first HSCT conditioning dose: * Plasma creatinine within 1.5 times the upper limit of normal for age. * Amylase within age-appropriate limits * Plasma conjugated bilirubin within ≤ 3x upper limit of normal for age unless attributable to Gilbert's Syndrome * ALT ≤ 5x upper limit of normal for age Baseline ECG within the month prior to study drug administration without known clinically significant abnormalities including pathologic prolongation of QTc A plan for scheduled, round-the-clock receipt of ondansetron, granisetron or palonosetron for antiemetic prophylaxis during administration of chemotherapy or HSCT conditioning. Negative pregnancy test if female of childbearing potential Patients of childbearing potential must consent to use adequate contraception (males and females) or agree to practice abstinence Parent or child able to speak a language in which the (modified Pediatric Adverse Event Rating Scale (PAERS) is available. Optional: Child participants in the optional assessment of nausea severity must be 4 to 18 years of age. Child and a parent/guardian must be English, Spanish or French-speaking. The Pediatric Nausea Assessment Tool58 (PeNAT) is validated in English-speaking children 4 to 18 years old with an English-speaking parent/guardian and has been translated into Spanish and French. The MAT is available in English, Spanish and French.

Design outcomes

Primary

MeasureTime frameDescription
Rate of CIV control during the acute phaseup to 8 daysComplete CIV control is no vomiting/retching and no use of breakthrough antiemetic agents during phase

Secondary

MeasureTime frameDescription
Association between PeNAT and MASCC Antiemesis Tool (MAT) scoresup to 1 monthtaking maximum daily PeNAT scale score and maximum nausea experience in MAT will estimate the degree of association between PeNAT and MAT
Impact of olanzapine on HSCT outcomes on incidence of GVHDFrom first HSCT conditioning dose until 100 days post-HSCTLooking at incidence of GVHD between the two arms
complete and partial CINV controlup to 1 monthComplete CIV control is no vomiting/retching and no use of breakthrough antiemetic agents during phase, Partial control is defined as no more than two vomits or retches during any 24-hr period
Safety profile of olanzapine based on toxicitiesup to 1 monthBased on descriptive statistics on reported toxicities.
Safety profile of olanzapine based on weightup to 1 monthBased on descriptive statistics on reported body weight
Safety profile of olanzapine based on Pediatric Adverse Event Rating Scale (PAERs)up to 1 monthBased on descriptive statistics on reported PAERs, will describe the most reported and most bothersome adverse events reported in the PAERs questionnaire.
Safety profile of olanzapine based on prolactinup to 1 monthBased on descriptive statistics on reported prolactin, will report incidence of abnormal prolactin values comparing the two arms
Safety profile of olanzapine based on amylaseup to 1 monthBased on descriptive statistics on reported amylase, will report incidence of abnormal amylase values comparing the two arms
Safety profile of olanzapine based on creatine phophotaseup to 1 monthBased on descriptive statistics on reported creatine phophotase, will report incidence of abnormal creatine phophotase values comparing the two arms
Safety profile of olanzapine based on triglyceridesup to 1 monthBased on descriptive statistics on reported triglycerides, will report incidence of abnormal triglyceride values comparing the two arms
Impact of olanzapine on HSCT outcomes on severity of GVHDFrom first HSCT conditioning dose until 100 days post-HSCTComparing the incidence of the different maximal grades of GVHD between the two arms
Impact of olanzapine on HSCT outcomes on incidence of veno-occlusive diseaseFrom first HSCT conditioning dose until 100 days post-HSCTLooking at incidence of veno-occlusive disease

Countries

Canada, India, United States

Contacts

PRINCIPAL_INVESTIGATORLee Dupuis, RPh, PhD

The Hospital for Sick Children

PRINCIPAL_INVESTIGATORMuhammad Ali, MD

The Hospital for Sick Children

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 28, 2026